Results 31 to 40 of about 101 (70)

G protein-coupled receptors and obesity. [PDF]

Front Endocrinol (Lausanne), 2023
Pocai A.
europepmc   +1 more source

Incretin analogues as cardiovascular agents: a state-of-the-art review. [PDF]

Front Endocrinol (Lausanne)
Araiza-Garaygordobil D, Rico-Fontalvo J, Hernández-Balbuena B, Vinay-Coro M, González-Arias M.   +4 more
europepmc   +1 more source

Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies. [PDF]

J Clin Med
Bijoch J.
europepmc   +1 more source

Pharmacological therapies for type 2 diabetes: future approaches. [PDF]

Diabetologia
Bailey CJ.
europepmc   +1 more source

The fourth controlled release society workshop on oral peptide administration. [PDF]

Front Drug Deliv
Brayden DJ, Buckley ST, Lewis AL.
europepmc   +1 more source

The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. [PDF]

Biosci Rep
Patil M, Piccinini F, Johnstone EKM, Casari I, Falasca M.   +4 more
europepmc   +1 more source

The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction. [PDF]

Medicina (Kaunas)
Lee RSM, Seah JM, Baqar S, Srivastava PM, Levelt E, Leet AS, MacIsaac AI, Ekinci EI, MacIsaac RJ.   +8 more
europepmc   +1 more source

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. [PDF]

Diabetes Ther
Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E.   +4 more
europepmc   +1 more source

A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. [PDF]

Pharmaceuticals (Basel)
Lee S, Song H, Kwon Y.
europepmc   +1 more source

Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction. [PDF]

J Cardiovasc Pharmacol
Biondi-Zoccai G, Galli M, Booz GW.
europepmc   +1 more source